Kornimate/medical-research-clean huggingface dataset:
presternal magnesium with bupivacain versus bupivacain only for postoperative pain relief in open heart surgery

Conditions: Postoperative Pain

Summary: effective pain relief after cardiac surgery has assumed importance with the introduction of fast track discharge protocols that requires early weaning from mechanical ventilation. inadequate pain control reduces the capacity to cough, mobility, increases the frequency of atelectasis, and prolongs recovery. infiltration of local anesthetics near the surgical wound has shown to improve early postoperative pain in various surgical procedures. magnesium is the fourth most plentiful cation in our body. it has antinociceptive effects in animal and human models of pain.

effective pain relief after cardiac surgery has assumed importance with the introduction of fast track discharge protocols that requires early weaning from mechanical ventilation. inadequate pain control reduces the capacity to cough, mobility, increases the frequency of atelectasis, and prolongs recovery. a major cause of pain after cardiac surgery is the median sternotomy particularly on the first two postoperative days. the most often used analgesics in these patients are parenteral opioids which can lead to undesirable side-effects as sedation, respiratory depression, nausea, and vomiting. infiltration of local anesthetics near the surgical wound has shown to improve early postoperative pain in various surgical procedures. magnesium is the fourth most plentiful cation in our body. it has antinociceptive effects in animal and human models of pain. it has been mentioned in a systematic review that it may be worthwhile to further study the role of supplemental magnesium in providing perioperative analgesia, because this is a relatively harmless molecule, is not expensive and also because the biological basis for its potential antinociceptive effect is promising. these effects are primarily based on physiological calcium antagonism, that is voltage-dependent regulation of calcium influx into the cell, and noncompetitive antagonism of n-methyl-d-aspartate (nmda) receptors. there is a need to evaluate and compare local magnesium with bupivacaine , in comparison to bupivacain

Eligibility criteria:
inclusion criteria: * 18-60 years old * american society of anesthesiologists physical status ii and iii * patients scheduled for open heart surgery with sternotomy exclusion criteria: * - emergency surgery * clinically significant kidney or liver disease * patients allergic to local anesthetic * patients with prolonged cpb time (\>120 min) * patients required intra-aortic balloon pump
effectiveness of four popular diet strategies for weight loss and cardiac risk reduction

Conditions: Obesity; Cardiovascular Disease; Metabolic Syndrome

Summary: a single-center randomized trial at an academic medical center in boston, mass, of overweight or obese adults with known hypertension, dyslipidemia, or fasting hyperglycemia. participants were enrolled starting july 18, 2000, and randomized to 4 popular diet groups until january 24, 2002.

objective: to assess adherence rates and the effectiveness of 4 popular diets (atkins, zone, weight watchers, and ornish) for weight loss and cardiac risk factor reduction. design, setting, and participants: a single-center randomized trial at an academic medical center in boston, mass, of overweight or obese adults with known hypertension, dyslipidemia, or fasting hyperglycemia. participants were enrolled starting july 18, 2000, and randomized to 4 popular diet groups until january 24, 2002. intervention: a total of 160 participants were randomly assigned to either atkins (carbohydrate restriction, n=40), zone (macronutrient balance, n=40), weight watchers (calorie restriction, n=40), or ornish (fat restriction, n=40) diet groups. after 2 months of maximum effort, participants selected their own levels of dietary adherence. main outcome measures: one-year changes in baseline weight and cardiac risk factors, and self-selected dietary adherence rates per self-report. outcome measures included body weight, total cholesterol, ldl-c, hdl-c, triglycerides, hscrp, insulin, glucose.

Eligibility criteria:
inclusion criteria: * bmi 27-42; * at least one metabolic cardiac risk factor exclusion criteria: * age under 18 years; * insulin therapy; * unstable chronic illness; * unwilling to follow dietary advice

Keywords: nutrition popular diets weight loss lifestyle counseling
establishment of voice analysis cohort for development of monitoring technology for dysphagia

Conditions: Deglutition Disorders

Summary: collection of basic data to develop a technique for monitoring the state of dysphagia using voice analysis.

* design: prospective study * inclusion criteria of the patient group * patients scheduled for vfss examination and normal person (without dysphagia) capable of recording voice (selected as a control group for comparison of voice indicators with patients with dysphagia) * patients who can record voices such as "ah for 5 seconds", "ah. ah. ah.", "umm\~\~\~" * inclusion criteria of the control group: patients unable to speak, patients who cannot follow along, if the vfss test is a retest * setting: hospital rehabilitation department * intervention: after obtaining the consent form for the patient scheduled for the vfss test, "ah for 5 seconds", after clearing the throat, "ah for 5 seconds", briefly cut with a high-pitched sound, "ah. ah. ah", close your lips lightly and make a "ummm\~\~\~\~" sound, and record 2 times each.

Eligibility criteria:
inclusion criteria: * patients with dysphagia and scheduled for vfss testing * patients who can record voice such as "ah for 5 seconds", "ah. ah. ah", or "um\~\~" * normal people (without dysphagia symptoms) who can record voice (additionally recruited for comparison of voice indicators with patients with dysphagia) exclusion criteria: * patients who cannot speak. * patients who cannot speak according to the researcher's instructions. * patients whose vfss test was reexamined
rehabilitation of balance function in patients with persistent postural perceptual dizziness.

Conditions: Persistent Postural Perceptual Dizziness

Summary: rehabilitation of balance function in patients with persistent postural perceptual dizziness: a longitudinal study

this study will be conducted to show the long term effect of combined vestibular rehabilitation incorporating optokinetic stimulation and virtual reality exercises on persistent postural perceptual dizziness patients. aim:1.evaluate the balance control function in patients with persistent postural perceptual dizziness using computerized dynamic posturography. 2.to study effect of rehabilitation using optokinetic stimulation and virtual reality on persistent postural perceptual dizziness patients. 3.to follow up patients after the vestibular rehabilitation therapy to study the persistence of improvement" if any" in patients with persistent postural perceptual dizziness . type of the study : prospective cohort and longitudinal study. sources of data : audio-vestibular medicine unit , sohag university hospital. study group : consists of 36 patients age ranged from 18-65 years suffering from symptoms of persistent postural perceptual vertigo. all subjects will be submitted to: a- detailed medical history, full history of dizziness. b-acoustic impedance test. c-basic audiological evaluation. d- vestibular assessment.

Eligibility criteria:
inclusion criteria: * age: from 18 years to 65 years old. * gender: males and females. * can withstand and willing to undergo repeated vestibular rehabilitation therapy .\*no history of any disease required to give treatment that could affect results. exclusion criteria: * neurological disorders, paresis, paralysis, motor disorder, ataxia, brain mass, multiple sclerosis and stroke with grade 4 muscle power or below. * otological disorders e.g. middle ear pathology (chronic suppurative otitis media, tumor). * psychiatric disorders e.g. schizophrenia and endogenous depression. * severely ill patients who would not tolerate vestibular rehabilitation therapy .
simvastatin in aneurysmal subarachnoid haemorrhage (stash) a multicentre randomised controlled clinical trial

Conditions: Subarachnoid Haemorrhage

Summary: intracranial bleeding from ruptured blood vessels (called a subarachnoid haemorrhage -sah) affects 7000 patients each year in the uk and is a source of considerable death and disability, even in young adults. recent observations indicate that these bleeds can cause reduced cerebral blood flow which leads to a bad outcome. high rates of death and disability occur, and are particularly prevalent when low cerebral blood flow results in stroke. prevention of cerebral artery spasm and improvement in blood vessel reflexes are the target of modern therapy. candidate drugs include statins which have an impeccable safety record and multiple potential beneficial actions (improve cerebral blood flow, reduce inflammatory processes, reduce adverse blood coagulation) following sah. the investigators plan to use a statin, simvastatin (40 mg) to improve cerebral blood flow and reduce inflammation. we have already completed a phase 11 study (n=80) which demonstrated potential benefits for acute statin therapy following sah, and the investigators now wish to conduct a multi-centre phase 111 study to explore any potential clinical benefits in a larger population (n=1600). the purpose is to see whether the positive effects of statins seen in our phase ii study translate into clinical benefits - both short term (e.g. reduced need for intensive care) and long term (outcome and wellbeing at 6 months).


Eligibility criteria:
inclusion criteria * patients (age 18 - 65 yr) in which the admitting neurosurgeon has confirmatory evidence of an aneurysm, either by ct angiography, mr angiography or dsa. * any clinical grade accepted provided a reasonable prospect of survival. * delay to randomisation and initiation of trial medication from the time of the presenting ictus does not exceed 96 hours. exclusion criteria * unsalvageable patients:fixed and dilated pupils after resuscitation, and/or a devastating scan, which precludes definitive therapy. * already taking statin therapy. * those taking warfarin - type drugs. * pregnancy. * known renal or hepatic impairment * suspected or known additional disease process, which threatens life expectancy (e.g.malignancy). * known or strong suspicion of drug abuse, alcoholism, or those who are unlikely to be amenable to 6 month follow up. * those already taking amiodarone, verapamil or potent cyp3a4 inhibitors.

Keywords: intracranial aneurysm
comparison the postoperative effects of local and systemic antibiotics applied with platelets rich fibrin

Conditions: Impacted Wisdom Tooth

Summary: the aim of this study was investigate the comparison of postoperative effects of local antibiotics mixed with platelet-rich fibrin and postoperative systemic antibiotic applications prescribed for mandibular impacted third molar tooth extraction. the study included a total of 75 patients with impacted mandibular third molar. patients were evaluated in 5 randomly separated groups. for the first and third group, platelets rich fibrin+ systemic antibiotics were applied into the tooth socket and for the second and fourth group, platelets rich fibrin + local antibiotics were applied, respectively. there was a control group which only platelets rich fibrin was applied into the socket. the outcome variables were pain, swelling, the number of analgesics taken, and trismus. these variables were also assessed based on first, second, third, and seventh days following the operation.


Eligibility criteria:
inclusion criteria: * the patient had no systemic diseases, no taken opioids for a long period, no current infections or acute pericoronitis, no smoke or drink alcohol, no pregnancy, the absence of allergy to penicillin and presence of penicillin allergy. exclusion criteria: * pericoronitis, no inflammation

Keywords: platelets rich fibrin systemic antibiotic local antibiotic comparison
comparison between biodentine and calcium hydroxide in the indirect pulp treatment on primary teeth

Conditions: Dental Caries

Summary: objective: the study's main purpose is to evaluate and compare the clinical and radiographic outcomes of biodentine and a light-activated calcium hydroxide based-liner (ultra-blend plus®) as indirect pulp treatment (ipt) liners, over the dentin-pulp complex of vital primary molars with carious lesions approaching the pulp. study design: 80 four-to-eight year-old patients were enrolled from a mexican university pediatric dentistry clinic. a split-mouth design trial is being conducted in order to compare both ipt interventions on 160 bilateral primary teeth, without signs or symptoms of irreversibly inflamed or degenerative pulp tissue. teeth were treated and restored with a preformed crown in a single session, and then closely followed-up for 1, 3, 6, 12, 18, and 24 months.

a split-mouth clinical trial was the design selected. clinical procedures: ipt procedures were carried out by three pediatric dentistry residents (e.k.c.g., r.a.v.v., and j.m.a.r.), previously trained in the clinical setting with a pilot sample of 10 similar child patients each. study participants received local anesthesia and rubber dam isolation, which was disinfected, followed by the remove of the carious peripheral dentin with high speed tungsten-carbide bur # 3, and air-water spray. then, the soft dentin layer was carefully removed with a sharply-edged sterilized hand excavator, based on tactile and visual standards, leaving only the hard dentin adjacent to the pulp ceiling. the cavity was thoroughly rinsed only with water and then dried with sterilized cotton pellets; no other special disinfection protocol was applied. the next step consisted in the placement of the correspondent liner over the remanent carious dentin layer, following the manufacturers' instructions, and according to the randomly assignment scheme previously described. in the case of the control group, the liner was cured undr 20 seconds of light exposure. all treated molar were restored with stainless steel preformed crowns (3m espe) cemented with glass ionomer (ketac-cem, 3m espe). one week later, the same procedure was repeated in the opposite tooth with the contrary ipt agent.

Eligibility criteria:
inclusion criteria: * at least one restorable first or second primary molar in each side of the mouth, affected by an occlusal cavitated active caries lesion in deep dentin. * cooperative patients. * participants were included in the trial after parental acceptance through a signed informed consent. exclusion criteria: * molars with mobility, spontaneous pain or fistula, and radiographic findings such as a carious lesion with no evidence of residual dentin over the pulp chamber or manifest pulp exposition. * normally internal root resorption or physiological root resorption less than 1/3. * presence of periradicular/furcal radiolucent lesions. * occurrence of a carious pulp exposure and bleeding during the operative procedure.

Keywords: indirect pulp treatment primary teeth biodentine calcium hydroxide split-mouth design
a study to describe the characteristics of patients treated with apremilast for plaque psoriasis in italian routine clinical practice

Conditions: Plaque Psoriasis

Summary: the darwin study is an italian multicenter, observational, cross-sectional study involving both a primary data collection (at enrollment visit) and secondary use of data (retrospective observation period). darwin will describe patients' characteristics in italian routine clinical practice as well as the medication utilization patterns, including needs and benefits form the patient's perspective.

the darwin study is anticipated to enroll 375 participants from 24 italian dermatologic departments and recruitment is expected to take approximately 20 months. participants must have started apremilast treatment 6 (±1) months prior enrollment in order to be considered eligible. the decision to prescribe apremilast falls within current practice according to the current decision-making process in the italian routine clinical practice and according to aifa prescribing information. no extra-procedures (diagnostic or monitoring) will be implemented and the assessment schedule reflects the routine clinical practice for psoriatic patients treated with apremilast. patients will be consecutively enrolled in the study and information will be collected as recorded in the medical chart before starting apremilast (as close as possible to the apremilast start date/index date), and/or directly observed during the enrolment visit. the study variables will describe patient disease and characteristics, apremilast utilization patterns, psoriasis severity a, extent and impact on patient wellbeing, apremilast safety profile and apremilast satisfaction.

Eligibility criteria:
inclusion criteria: 1. must have understood and voluntarily signed the informed consent and privacy form. 2. age ≥ 18 years at the time of signing the informed consent and privacy form. 3. patients with available hospital medical chart since the start of apremilast treatment ('index date'). 4. diagnosis of plaque psoriasis. 5. treatment with apremilast for plaque psoriasis, according to summary of product characteristics (smpc), started 6 (±1) months before enrollment. patients who interrupted apremilast treatment before enrollment will also be included. 6. ability to understand (read \& write) the italian language and to follow the study instructions. exclusion criteria: 1. refusal to participate in this study or current participation in the treatment phase of an interventional clinical trial. 2. started apremilast as part of a clinical trial, or previous apremilast use (prior to the index date).

Keywords: apremilast darwin dermatology retrospective observational psoriasis cross-sectional
effect of intravenous amantadine sulphate on disorders of consciousness

Conditions: Amantadine; Consciousness Disorders; Electroencephalography

Summary: double-blind, placebo-controlled, crossover ("within subjects") study with an a-b-a-b treatment scheme to investigate the neuromodulatory effects of intravenous amantadine sulphate at a single daily dose of 200 mg in patients with disorders of consciousness (unresponsive wakefulness syndrome and minimally conscious state) by integrating traditional neurobehavioral assessment with spectral analysis of electrocortical activity derived from 64-channel electroencephalography (eeg) recordings.

research hypothesis intravenous amantadine sulphate treatment (200 mg) over five days improves consciousness, defined as an increase in crs-r score of at least 3 points, and changes the band powers of the eeg in patients with disorder of consciousness admitted in a neurorehabilitation department.

Eligibility criteria:
inclusion criteria: adults with disorders of consciousness due to acquired brain injury classified according to international guidelines based on crs-r evaluation as unresponsive wakefulness syndrome/vegetative state (uws/vs) or minimally conscious state (mcs) either in the subacute or chronic stage exclusion criteria: * age \< 18 years * history of epileptic seizures/status epilepticus * scalp defects * pregnancy * severe uncompensated heart failure (nyha iv) * atrioventricular block (av block) second-degree and third-degree * known bradycardia (below 55 beats/minute) * known long qt interval (qtc according to bazett \> 420 ms * history of serious ventricular arrhythmias * hypokalemia or hypomagnesemia * impaired renal function

Keywords: doc = disorders of consciousness psd = power spectral density amantadine sulphate eeg
return to work after hand injury: the role of medical, demographic and psycho-social factors

Conditions: Hand Injury

Summary: the purpose of this study is to investigate the extent of return to work (rtw) after traumatic hand injury and to identify factors that are related to rtw.

rtw is one of the main rehabilitation outcomes after injury, the loss of the ability to work may have psychological as well as economic impact on the injured person. time off work is also a burden to the economic system, associated with loss of work days, sick leave and national insurance payment. hand injury can cause limitations in function, therefore influence the ability to work. review of the literature reveals that time off work after hand injury ranges from a few days to a year and more. factors associated with time off work include medical, socio-economic and psychosocial factors. only a few studies have been conducted in israel to investigate rate of rtw after hand injury and factors that affect rtw . the aim of this study is to explore the extent of rtw after traumatic hand injury and to examine the relationship between several factors - medical, demographic and psychosocial and rtw. this, in order to identify prognostic factors that can be treated during rehabilitation. there is no preliminary hypothesis made about the relationships between the factors and rtw. this study is also retrospective and prospective since it examine individuals under-going occupational therapy treatment and individuals who have been treated in the past.

Eligibility criteria:
inclusion criteria: * the individual worked until he/she was injured * traumatic hand injury including: wrist fractures, fingers fractures, tendon injury, nerve injury, crush injury, finger amputation exclusion criteria: * non traumatic hand injury (such as cts) * mallet finger * burns * injury in several organs
exploration of ejaculation changing mechanism after surgery for benign prostatic hyperplasia

Conditions: Prostate; Ejaculation; Benign Prostatic Hyperplasia

Summary: every year in france, more than 60 000 people are operated for benign prostatic hyperplasia (bph). this surgery is accompanied by a change or even a loss of ejaculations externalized what constitutes the main constraint for patients. empirically, the investigators talk to the patient "retrograde ejaculation" to explain a possible loss of ejaculation. yet the underlying mechanism of this modification or loss of ejaculation remains completely unknown. yet the underlying mechanism of this modification or loss of ejaculation remains completely unknown. no study could not determine whether the predominant mechanism was a real retrograde ejaculation or aspermia. moreover, technical changes are sometimes tempted to preserve antegrade ejaculation but no scientific rationale can not validate.

every year in france, more than 60 000 people are operated for benign prostatic hyperplasia (bph). this surgery is accompanied by a change or even a loss of ejaculations externalized what constitutes the main constraint for patients. empirically, the investigators talk to the patient "retrograde ejaculation" to explain a possible loss of ejaculation. yet the underlying mechanism of this modification or loss of ejaculation remains completely unknown. no study could not determine whether the predominant mechanism was a real retrograde ejaculation or aspermia. moreover, technical changes are sometimes tempted to preserve antegrade ejaculation but no scientific rationale can not validate.

Eligibility criteria:
inclusion criteria: * man, at least 18 years, which is scheduled for a bph surgery * sexually active * measurement of residual postvoid less than 6 months * patients accepting the constraints of the study * signed consent * affiliate or beneficiary of social security system. exclusion criteria: * patients unable to understand the study or to give consent * patients with known infertility * patients previously operated prostate * patients previously treated with a natural prostate treatment (radiotherapy, microwave, radio frequency, ultrasound) * patients with known urethral stenosis before surgery * patient with impaired preoperative in ejaculation * patient under guardianship or under judicial protection * patient subject to psychiatric care

Keywords: ejaculation benign prostatic hyperplasia prostate